Table 1. Patient Characteristics.
| No | Cluster | Sex | Age at Dx (y) | Histologic Dx | MGMT methylated? | Line of therapy* | Treatment regimen until PET investigation | Concomitant dexamethasone treatment? | Wks from last Rx | Follow-up MRI + Clin. | Follow-up Time (m) | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | m | 29 | AA | yes | 1 | P: B,RT+TMZ | no | 7 | stable | 27.2 | >26.7 | >27.2 |
| 3 | 1 | m | 45 | GBM* | yes | 2 | P: B,TMZ; 1R: R,RT,PC | yes | 16 | prog. | 16.4 | 8.4 | 16.4 |
| 4 | 1 | f | 40 | AOA | yes | 4 | P: pR; 1R: TMZ; 2R: TMZ; 3R: pR,RT,CCNU | no | 34 | prog. | 126.4 | >26.1 | >126.4 |
| 10 | 1 | m | 43 | GBM* | no | 1 | P: pR,RT,PC | no | 37 | prog. | 24.1 | 8.0 | 24.1 |
| 12 | 1 | m | 70 | GBM | yes | 2 | P: pR,RT+TMZ,TMZ; 1R: R,TMZ | no | 139 | prog. | 45.1 | 4.1 | 45.1 |
| 14 | 1 | f | 68 | GBM | yes | 1 | P: cR,RT+TMZ,TMZ | yes | 10 | prog. | 23.4 | >22.1 | >23.4 |
| 5 | 2 | f | 49 | GBM | no | 1 | P: pR,RT+TMZ,TMZ | no | 52 | prog. | 34.1 | 4.6 | 34.1 |
| 6 | 2 | m | 61 | GBM | yes | 2 | P: cR,RT+TMZ,TMZ; 1R: R,RT,CCNU/TMZ | no | 25 | prog. | 23.5 | >13.3 | >23.5 |
| 8 | 2 | m | 60 | GBM | yes | 1 | P: cR,RT+TMZ,TMZ | no | 33 | prog. | 11.3 | 2.2 | 11.3 |
| 13 | 2 | m | 54 | GBM | yes | 1 | P: pR,RT+TMZ | no | 4 | prog. | 10.0 | 6.0 | 10.0 |
| 2 | 3 | m | 59 | GBM | yes | 1 | P: cR,RT+TMZ/CCNU, TMZ/CCNU | no | 95 | stable | 44.3 | >21.7 | >44.3 |
| 7 | 3 | f | 47 | AA | yes | 1 | P: B,RT+TMZ,TMZ | no | 25 | stable | 27.5 | 16.7 | 27.5 |
| 9 | 3 | f | 66 | GBM | yes | 1 | P: cR,RT+TMZ,TMZ | no | 48 | prog. | 21.7 | 5.1 | 21.7 |
| 11 | 3 | m | 50 | GBM | yes | 2 | P: cR,RT+TMZ,TMZ; 1R: R,RT+CCNU/TMZ,CCNU/TMZ | no | 41 | stable | 49.3 | 13.9 | 49.3 |